Related references
Note: Only part of the references are listed.Cabazitaxel in patients with advanced solid tumours: Results of a Phase I and pharmacokinetic study
V. Dieras et al.
EUROPEAN JOURNAL OF CANCER (2013)
A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: A phase I/II study
C. Villanueva et al.
EUROPEAN JOURNAL OF CANCER (2011)
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
Johann Sebastian de Bono et al.
LANCET (2010)
Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors
Alain C. Mita et al.
CLINICAL CANCER RESEARCH (2009)
A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients
X. Pivot et al.
ANNALS OF ONCOLOGY (2008)
Population pharmacokinetic modelling of unbound and total plasma concentrations of paclitaxel in cancer patients
A Henningsson et al.
EUROPEAN JOURNAL OF CANCER (2003)
Mechanism-based pharmacokinetic model for paclitaxel
A Henningsson et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check
Y Yano et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2001)
Clinical pharmacokinetics of capecitabine
B Reigner et al.
CLINICAL PHARMACOKINETICS (2001)
Share Paper
